Abstract
We report a case of pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following adjuvant chemotherapy. A 51-year-old woman with stage IIIA adenocarcinoma received left lower lobe lobectomy in July, 2006. And then combination chemotherapy with paclitaxel and cisplatin was given to the patient. In five days after completion of second cycle of the chemotherapy, she visited emergency room because of general weakness and seizure. Her brain MRI was shown to be no evidence of brain metastasis. Serum sodium, urine and plasma osmolarities were 117mEq/L, 589 and 244mOsm/kg, respectively. She was improved with fluid restriction. Although occurrence of SIADH following chemotherapy is rare, physician should give an attention the potential for development of SIADH in the course of chemotherapyin non-small cell lung cancer patient.
References
1. List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986. 4:1191–1198.
2. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995. 238:97–110.
3. Tho LM, Ferry DR. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety? Postgrad Med J. 2005. 81:e17.
4. Monsieur I, Meysman M, Noppen M, de Greve J, Delhove O, Velckeniers B, et al. Non-small-cell lung cancer with multiple paraneoplastic syndromes. Eur Respir J. 1995. 8:1231–1234.
5. Karthik S, Roop R, Mediratta NK. Adenocarcinoma of lung presenting with dysgeusia. Thorax. 2004. 59:84.
6. Nakazato Y, Imai K, Abe T, Tamura N, Shimazu K. Unpleasant sweet taste: a symptom of SIADH caused by lung cancer. J Neurol Neurosurg Psychiatry. 2006. 77:405–406.
7. Kagawa K, Fujitaka K, Isobe T, Yamasaki M, Miyazaki M, Oguri T, et al. Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. Intern Med. 2001. 40:1020–1023.
8. Ishii K, Aoki Y, Sasaki M, Tanaka K. Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cisplatin chemotherapy. Gynecol Oncol. 2002. 87:150–151.
9. Otsuka F, Hayashi Y, Ogura T, Hayakawa N, Ikeda S, Makino H, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin. Intern Med. 1996. 35:290–294.
10. Littlewood TJ, Smith AP. Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin. Thorax. 1984. 39:636–637.
11. Fukabori T, Nakamura T, Kida T, Fujita Y, Goto T, Hiramori N, et al. Syndrome of inappropriate antidiuretic hormone secretion following cisplatinum and vindesine administration in a patient with squamous cell carcinoma of the lung. Gan To Kagaku Ryoho. 1991. 18:1213–1216.
12. Langer-Nitsche C, Luck HJ, Heilmann M. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer. Acta Oncol. 2000. 39:1001.
13. Bjornson DC, Stephenson SR. Cisplatin-induced massive renal tubular failure with wastage of serum electrolytes. Clin Pharm. 1983. 2:80–83.
14. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988. 108:21–25.
15. Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol. 2002. 25:344–346.
16. Levin L, Sealy R, Barron J. Syndrome of inappropriate antidiuretic hormone secretion following disdichlorodiammineplatinum II in a patient with malignant thymoma. Cancer. 1982. 50:2279–2282.